News - ANAVEX

View all Alzheimer's Disease Anavex2-73 Events News Releases PDD PIPELINE Press Uncategorized

Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease

Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC)

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)